Mechanism and strategy of the secondary resistance to EGFR-TKI in patients with lung cancer
10.3760/cma.j.issn.1673-422X.2015.01.015
- VernacularTitle:肺癌EGFR-TKI继发耐药的主要机制与应对策略
- Author:
Siwen LIU
;
Shaorong YU
;
Jifeng FENG
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Drug resistance,neoplasm;
EGFR-TKI
- From:
Journal of International Oncology
2015;42(1):56-59
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is one of the most important targeted drugs for lung cancer patients carrying EGFR sensitive mutations.However,almost all patients that are effective to this treatment will eventually develop secondary resistance to EGFR-TKI.The most accepted mechanisms of resistance mainly include T790M mutation,MET amplification,PIK3CA mutation,down-regulation of PTEN expression and activation of Fas-transcription factor-κB.Recent years,many new drugs are developed to overcome this resistance.Although most of drugs are in the stages of cell or animal experiment,some new drugs get positive clinical results.
